Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Microbiome Modulation With CBM588 in Combination With Pembrolizumab for Adjuvant Therapy of High-Risk, Resected Renal Cell Carcinoma (RCC)

NCT07037004 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT07037004
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07037004 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Microbiome Modulation With CBM588 in Combination With Pembrolizumab for Adjuvant Therapy of High-Risk, Resected Renal Cell Carcinoma (RCC)
Lead sponsor
City of Hope Medical Center
Phase
Phase 2
Overall status
Recruiting
Start date
January 1, 2027
Completion date
October 24, 2028
Enrollment
62 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

clear cell renal cell carcinoma, sarcomatoid renal cell carcinoma, stage ii renal cell cancer ajcc v8, stage iii renal cell cancer ajcc v8, stage iv renal cell cancer ajcc v8